Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda

  • End date
    Dec 24, 2023
  • participants needed
  • sponsor
    Makerere University
Updated on 24 January 2021
bcg vaccine


BCG vaccination may have non-specific effects (NSE) i.e., additional benefits on childhood morbidity and mortality that are separate the vaccine's effect on the incidence of disseminated tuberculosis. Though the available literature is mostly from observational study designs, and is fraught with controversy, BCG vaccination at birth, in a high risk population of HIV exposed children, may protect infants against serious infections other than TB. Yet, other studies indicate that giving BCG later in infancy, when the immune system is more mature, may offer even greater protection. The appropriate timing of BCG vaccination could therefore be up for revision. This study will therefore compare BCG vaccination at birth with BCG vaccination at 14 weeks of age in HIV exposed (HE) babies.

Methods: This is an individually randomized clinical trial in 4,500 HIV exposed infants. The intervention is an intra-dermal administration of 0.05 ml of BCG vaccine within 24 hours of birth while the comparator will be an intra-dermal administration of 0.05ml of BCG vaccine at 14 weeks of age.

The main study outcomes include:

  1. Severe illness in the first 14 weeks of life,
  2. TNF, IL-1b, IL-6 and IFN- in response to mycobacterial and non-mycobacterial antigens and
  3. Severe illness in the first 14-52 weeks and 0-52 weeks of life.

The study will be carried in two health Center IIIs and a health center IV in Uganda.

Implications: A well-timed BCG vaccination could have important additional benefits in HE infants. This trial could inform the development of programmatically appropriate timing of BCG vaccination for HE infants.

Condition Malaria Vaccines, Malaria, Septicemia, Diarrhea, Sepsis and Septicemia, Recurrent Diarrhea, Severe Illness, Lower Respiratory Infection, LRTI, Lower Respiratory Tract Infection, Clostridium Difficile-Associated Diarrhea, diarrhoea, loose stools, chest infection, sepsis, sepsis syndrome
Treatment BCG at birth, Control arm: Delayed BCG
Clinical Study IdentifierNCT02606526
SponsorMakerere University
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age less than or equal to 1 yrs?
Gender: Male or Female
Do you have any of these conditions: Malaria or Lower Respiratory Infection or Sepsis and Septicemia or Diarrhea or Clostridium Difficile-Associated Diarrhea or Septicemia or Malaria Vacc...?
Do you have any of these conditions: diarrhoea or Lower Respiratory Infection or LRTI or Malaria or loose stools or Severe Illness or sepsis or sepsis syndrome or Malaria Vaccines or Recu...?
A baby born at a participating study clinic will be included if s/he
has a mother with a positive HIV test (ELISA or rapid test)
is receiving peri-exposure prophylaxis as part of the standard/national guidelines in Uganda
has a mother that is of legal age for participation in clinical research studies in Uganda or is an emancipated minor
has a mother/caregiver that resides within the study area, is not intending to move out of the area in the next 4 months and is likely to be traceable for up to 12 months
has a mother/caregiver that gives informed consent to random assignment to either of the two trial arms
has a mother that has received antiretroviral therapy (ART) for at least 4 weeks

Exclusion Criteria

A new-born child will be excluded if she/he has
serious congenital malformation(s)
severe illness requiring hospitalization
a birth weight < 2.0 kg
a mother participating in another clinical trial on the day of enrolment or a mother who will participate in another clinical trial within the next month
a mother or other household member with symptoms and signs of tuberculosis on the day of enrolment
a severely ill mother with (a) condition(s) requiring hospitalization
a baby with an Apgar score at 5 minutes <7
a twin or triplet
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note